Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Melanoma
  • Skin Neoplasms

abstract

  • There was no difference in survival time and only a small, statistically nonsignificant increase in tumor response for stage IV melanoma patients treated with the Dartmouth regimen compared with dacarbazine. Dacarbazine remains the reference standard treatment for stage IV melanoma.

publication date

  • September 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10561349

Additional Document Info

start page

  • 2745

end page

  • 51

volume

  • 17

number

  • 9